Cognition Therapeutics, Inc. (CGTX) Sets FDA Type C Meeting to Align DLB Phase 3 Endpoint

Cognition Therapeutics scheduled an FDA Division of Neurology Type C meeting on Oct. 20, 2026 to align on the proposed primary endpoint for a planned registrational Phase 3 trial of zervimesine (CT1812) in DLB with psychosis.Material DetailsContext by AI AnalystThis is a mid-cycle regulatory step t…